Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy

被引：0
|
作者：
Michalaki, V.
Gennatas, S.
Gennatas, C. G.
机构：
[1] Univ Athens, Arete Hosp, Athens, Greece
[2] Univ Athens, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5116
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer
    Levy, T
    Inbar, M
    Menczer, J
    Grisaru, D
    Glezerman, M
    Safra, T
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 686 - 690
  • [22] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [23] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [24] Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
    Chelariu-Raicu, Anca
    Levenback, Charles
    Slomovitz, Brian
    Wolf, Judith
    Bodurka, Diane C.
    Kavanagh, John J.
    Morrison, Christopher
    Gershenson, David
    Coleman, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1768 - 1774
  • [25] Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer
    Le, T.
    Hopkins, L.
    Baines, K. A.
    Rambout, L.
    Al Hayki, M.
    Fung, M. Kee Fung
    GYNECOLOGIC ONCOLOGY, 2006, 102 (01) : 49 - 53
  • [26] A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy
    Spannuth, Whitney A.
    Leath, Charles A., III
    Huh, Warner K.
    Barnes, Mack N., III
    Davidson, Susan A.
    Kilgore, Larry C.
    Partridge, Edward E.
    Austin, J. Maxwell, Jr.
    Alvarez, Ronald D.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 591 - 595
  • [27] PHASE 2 TRIAL OF DOSE DENSE (WEEKLY) PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R.
    Dorman, D.
    Lee, J.
    Apte, S.
    Chon, H.
    Shahzad, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 877 - 877
  • [28] A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma
    Rodriguez, M
    Method, MW
    Lewandowski, G
    Vaccarello, L
    Ansari, RH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 464S - 464S
  • [29] Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
    Osman, Mohammed A.
    Elkady, Mohammad S.
    Nasr, Khalid E.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 35 - 41
  • [30] Topotecan (TOPO) +/- cisplatin for intraperitoneal (IP) consolidation after platinum-based induction of epithelial ovarian cancer (EOC)
    Andreopoulou, Eleni
    Chen, Thomas
    Liebes, Leonard
    Curtin, John
    Hochster, Howard
    Muggia, Franco
    ANNALS OF ONCOLOGY, 2006, 17 : 175 - 176
12345